Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 114

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 114
---
 |             -2,891 | ​ | $ |            -8,634 |
| Pro forma weighted average shares outstanding, basic and diluted         | ​ | ​                  |         26,714,633 | ​ | ​ |        26,714,633 |
| Pro forma net loss per share, basic and diluted                          | ​ | $                  |              -0.11 | ​ | $ |             -0.32 |
|                                                                          | ​ | ​                  |                  ​ | ​ | ​ |                   |
| Pro forma weighted average shares calculation, basic and diluted         | ​ | ​                  |                  ​ | ​ | ​ |                   |
| Iris public stockholders                                                 | ​ | ​                  |            114,633 | ​ | ​ |           114,633 |
| Sponsor and independent directors                                        | ​ | ​                  |          6,900,000 | ​ | ​ |         6,900,000 |
| Deferred underwriting commissions                                        | ​ | ​                  |            700,000 | ​ | ​ |           700,000 |
| Equity PIPE Investor                                                     | ​ | ​                  |          1,500,000 | ​ | ​ |         1,500,000 |
| Liminatus Members                                                        | ​ | ​                  |         17,500,000 | ​ | ​ |        17,500,000 |
| Pro forma weighted average Class A shares calculation, basic and diluted | ​ | ​                  |         26,714,633 | ​ | ​ |        26,714,633 |

74

<div align='center'>MARKET INFORMATION OF OUR SECURITIES</div>

Market Information

Our Common Stock and Public Warrants are listed on The Nasdaq Global Market and The Nasdaq Capital Market, respectively, and began trading on Nasdaq under the symbols “LIMN” and “LIMNW,” respectively, on May 1, 2025. On July 23, 2025, the last reported sales price of our Common Stock was $6.47 per share and the last reported sales price of our Public Warrants was approximately $0.2775 per warrant. As of July 23, 2025, there were approximately 7 holders of record of our Common Stock, 1 holder of record of the Public Warrants, and 1 holder of the Private Warrants. Such numbers do not include beneficial owners holding our securities through nominee names.

Dividend Policy

We have not paid any